PRESC1SE-MI
PRospective Evaluation of the European Society of Cardiology 0/1-hour Algorithm's Safety and Efficacy for Triage of Patients With Suspected Myocardial Infarction (PRESC1SE-MI)
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 67,624 emergency presentations with suspected myocardial infarction, the ESC 0/1-hour troponin algorithm was non-inferior to the 0/3-hour algorithm for death or type 1 myocardial infarction at 30 days, and length of stay.
Disegno
International, investigator-initiated, pragmatic, stepped-wedge, cluster-randomised, controlled trial with masked (blinded) endpoint adjudication at 19 hospitals in ten countries; hospitals using the ESC 0/3-hour pathway (blood draws 0 h and 3 h) as standard care were randomised to implement the ESC 0/1-hour pathway (blood draws 0 h and 1 h) after 6 months (early implementation) or 12 months (late implementation); consecutive adults with acute non-traumatic chest discomfort and suspected myocardial infarction enrolled Dec 1, 2020–Dec 31, 2024; 30-day follow-up; non-inferiority for safety (margin OR 1.3) and superiority for efficacy; full analysis set
Esito
Co-primary — (1) composite of all-cause death or type 1 myocardial infarction within 30 days of the index presentation (safety); (2) length of stay in the emergency department, from presentation to discharge or transfer (efficacy)
Rilevanza
2Importante — uno dei diversi pilastri.
RisultatoSafety: death from any cause or new type 1 myocardial infarction within 30 days in 454/36 464 (1.2%) with the 0/3-hour pathway vs 341/31 160 (1.1%) with the 0/1-hour pathway (adjusted OR 0.93, 95% CI 0.77-1.13; p = 0.0004 for non-inferiority, margin OR 1.3). Efficacy: median emergency department length of stay 309 min (IQR 203-470) vs 309 min (207-474); ratio of adjusted median times 1.00 (95% CI 0.97-1.02), two-sided p = 0.65 — non-inferior for safety, no reduction in length of stay.
Boeddinghaus J, Bima P, Crisanti L, et al. Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial. Lancet. 2026; published online Aug 29. doi:10.1016/S0140-6736(26)01654-5 10.1016/s0140-6736(26)01654-5